PharmiWeb.com - Global Pharma News & Resources
04-Feb-2019

Global Allergic Conjunctivitis Markets, 2019-2025: Patients & Treated Patients by Countries, Disease Types, Drugs Profiles and Companies - ResearchAndMarkets.com

The "Global Allergic Conjunctivitis Market, Patients, Treated Patients, by Countries (India, China, Japan, US, UK, etc), Disease Type (SAC, PAC, VKC, AKC, GPC), Drugs Profile (Zerviate, OTX-DP, ADX-102, PRT-2761) Companies, Growth Drivers & Challenges" report has been added to ResearchAndMarkets.com's offering.

The Allergic Conjunctivitis Market is expected to be more than a USD 2 Billion market by 2025.

Global allergic conjunctivitis market will grow due to the increasing prevalence of various allergic conjunctivitis, development in medical infrastructure in the developing countries, growing awareness about allergic conjunctivitis among people, increasing aging population and upcoming therapies such as Zerviate, ADX-102, PRT-2761, OTX-DP etc.

Allergic conjunctivitis is classified mainly in five types: Seasonal Allergic Conjunctivitis (SAC), Perennial Allergic Conjunctivitis (PAC), Vernal Keratoconjunctivitis (VKC), Atopic Keratoconjunctivitis (AKC) and Giant Papillary Conjunctivitis (GPC).

China Dominates the Global Allergic Conjunctivitis Patient Population

In this report, we have shown a complete insight of country analysis of allergic conjunctivitis patient population. The covered countries are; India, China, Japan, United States, United Kingdom, France, Germany, Italy, and Spain. China dominates the global allergic conjunctivitis patient population numbers.

The United States is the leading Country in the Global Allergic Conjunctivitis Market

Allergic conjunctivitis market is growing across all parts of the world. Market growth rates vary in the countries covered in the report India, China, Japan, United States, United Kingdom, France, Germany, Italy, and Spain. The United States is a leading country in the global allergic conjunctivitis market due to growing awareness, strong healthcare support system and large patient population.

Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC) Hold Majority of Market in the Global Allergic Conjunctivitis Market

On the basis of disease type, global Allergic conjunctivitis market is further segmented into seasonal allergic conjunctivitis (SAC) & perennial allergic conjunctivitis (PAC) market, vernal keratoconjunctivitis (VKC) market, atopic keratoconjunctivitis (AKC) market, and giant papillary conjunctivitis (GPC) market, globally. Seasonal allergic conjunctivitis (SAC) & perennial allergic conjunctivitis (PAC) hold the majority of market share in the global allergic conjunctivitis market.

Allergic Conjunctivitis Pipe Line Drugs are Key Strength for this Market Place

In the global allergic conjunctivitis market, allergic conjunctivitis pipeline drugs will play a major role in the growth of this market. At present several drugs such as Zerviate, OTX-DP, ADX-102, PRT-2761, CVXL-0074, AK-002, Bertilimumab, Reproxalap, ST-266, SYL-116011 etc. are in preclinical, IND, Phase I, Phase II and Phase III stage.

The report has been analyzed from 9 Major Viewpoints:

1. Global Allergic Conjunctivitis Market

2. Global Allergic Conjunctivitis Market Share, Disease Type Market Share, Patients Share, Treated Patients Share

3. Country Allergic Conjunctivitis Market

4. Country Allergic Conjunctivitis Patients Population

5. Country Allergic Conjunctivitis Treated Patients Population

6. Disease Type Allergic Conjunctivitis Market

7. Allergic Conjunctivitis Drugs Pipeline

8. Growth Drivers and Challenges

9. Key Allergic Conjunctivitis Companies Initiatives and Financial Insight

Countries Covered

  • India
  • China
  • Japan
  • United States
  • United Kingdom
  • France
  • Germany
  • Italy
  • Spain

Disease Type Covered

  • Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC)
  • Vernal Keratoconjunctivitis (VKC)
  • Atopic Keratoconjunctivitis (AKC)
  • Giant Papillary Conjunctivitis (GPC)

Drugs Profiles Covered

  • Zerviate
  • OTX-DP
  • ADX-102
  • PRT-2761
  • CVXL-0074
  • AK-002
  • Bertilimumab
  • Reproxalap
  • ST-266
  • SYL-116011

Companies Covered

  • Santen Pharmaceutical
  • Alcon (Novartis)
  • Portola Pharmaceuticals
  • Ocular Therapeutix

For more information about this report visit https://www.researchandmarkets.com/research/vm2m48/global_allergic?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190204005406/en/

Editor Details

Last Updated: 04-Feb-2019